New research found no difference in rates of preterm births after adjusting for other risk factors.
Researchers claim immunotherapy may offer improved outcomes for patients experiencing HRP ovarian cancer.
Clinical trials for disease-modifying therapy for Alzheimer’s disease are underway.
Researchers at St. Jude Children’s Research Hospital found that adding a novel anti-disialoganglioside GD2 (anti-GD2) monoclonal antibody to the standard therapy for children newly diagnosed with high-risk neuroblastoma significantly enhanced response to treatment and improved survival. Their findings could be transformative if additional studies can produce similar results.
- 1 of 255
- next ›